White matter disease

Stroke Genetics

Volumn , Issue , 2013, Pages 171-188

  Rost, Natalia S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888037151     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-209-4_11     Document Type: Chapter

References (93)

1. Rost N. Just in time: an update on continuum neurogenetics. Continuum: Lifelong Learn Neurol. 2011;17(2):245.
2. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet. 2003;361(9374): 2046.
3. Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de Andrade M. Heritability of leukoaraiosis in hypertensive sibships. Hypertension. 2004;43(2):483-7.
4. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14.
5. Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology. 1999;53(1):132-9.
6. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28(3):652-9.
7. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology. 2008;71(11):804-11.
8. Longstreth WT, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the cardiovascular health study. Stroke. 1996;27(8):1274-82.
9. de Leeuw FE, de Groot JC, Bots ML, Witteman JC, Oudkerk M, Hofman A, et al. Carotid atherosclerosis and cerebral white matter lesions in a population based magnetic resonance imaging study. J Neurol. 2000;247(4):291-6.
10. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127 (Pt 1):212-9.
11. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, Sacco RL, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke. 2005;36(6):1207-11.
12. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, et al. Stroke risk pro file predicts white matter hyperintensity volume: the Framingham Study. Stroke. 2004;35(8): 1857-61.
13. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet. 2003;361(9374):2046-8.
14. Longstreth Jr WT, Arnold AM, Beauchamp Jr NJ, Manolio TA, Lefkowitz D, Jungreis C, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke. 2005; 36(1):56-61.
15. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke. 2005;36(7):1410-4.
16. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112(6): 900-5.
17. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol. 1986;19:253-62.
18. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993; 43:1683-9.
19. Fernando MS, O'Brien JT, Perry RH, English P, Forster G, McMeekin W, Slade JY, Golkhar A, Matthews FE, Barber R, Kalaria RN, Ince PG. Comparison of the pathology of cerebral white matter with post-mortem magnetic resonance imaging (MRI) in the elderly brain. Neuropathol Appl Neurobiol. 2004;30:385-95.
20. Opherk C, Peters N, Holtmannspotter M, Gschwendtner A, Muller-Myhsok B, Dichgans M. Heritability of MRI lesion volume in CADASIL: evidence for genetic modi fiers. Stroke. 2006; 37(11):2684-9.
21. Kalaria RN, Viitanen M, Kalimo H, Dichgans M, Tabira T. The pathogenesis of cadasil: an update. J Neurol Sci. 2004;226:35-9.
22. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord. 2002;14(3): 161-6.
23. Tian J, Shi J, Bailey K, Mann DM. Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in alzheimer's disease. Neuropathol Appl Neurobiol. 2004;30:46-56.
24. ∗ annex - supplemental online-only content. Stroke. 2006;37(6):1391-8.
25. Manolio TA, Burke GL, O'Leary DH, Evans G, Beauchamp N, Knepper L, et al. Relationships of cerebral MRI findings to ultrasonographic carotid atherosclerosis in older adults: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19(2):356-65.
26. Kuller LH, Longstreth Jr WT, Arnold AM, Bernick C, Bryan RN, Beauchamp Jr NJ. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke. 2004;35(8):1821-5.
27. Wolfson L, Wei X, Hall CB, Panzer V, Wakefield D, Benson RR, et al. Accrual of MRI white matter abnormalities in elderly with normal and impaired mobility. J Neurol Sci. 2005;232(1-2):23.
28. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61(10):1531-4.
29. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology. 2001;56(11):1539-45.
30. O'Brien JT, Firbank MJ, Krishnan MS, van Straaten ECW, van der Flier WM, Petrovic K, et al. White matter hyperintensities rather than lacunar infarcts are associated with depressive symptoms in older people: the LADIS Study. Am J Geriatr Psychiatry. 2006;14(10):834-41.
31. Neumann-Haefelin T, Hoelig S, Berkefeld J, Fiehler J, Gass A, Humpich M, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006;37(10):2463-6.
32. Ay H, Arsava EM, Rosand J, Furie KL, Singhal AB, Schaefer PW, Wu O, Gonzalez RG, Koroshetz WJ, Sorensen AG. Severity of leukoaraiosis and susceptibility to infarct growth in acute stroke. Stroke. 2008;39(5):1409-13.
33. Arsava EM, Rahman R, Rosand J, Lu S, Rost NS, Smith EE, Singhal AB, Lev MH, Furie KL, Koroshetz WJ, Sorensen AG, Ay H. Severity of leukoaraiosis predicts clinical outcome after ischemic stroke. Stroke. 2009;72(16):1403-10.
34. Kissela B, Lindsell CJ, Kleindorfer D, Alwell K, Moomaw CJ, Woo D, et al. Clinical prediction of functional outcome after ischemic stroke: the surprising importance of periventricular white matter disease and race. Stroke. 2009;40(2):530-6.
35. Breteler MMB, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JHW, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology. 1994;44(7):1246-52.
36. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: the ARIC Study. Stroke. 1996;27(12):2262-70.
37. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk pro file from the Framingham Study. Stroke. 1991;22(3):312-8.
38. Khatri M, Wright CB, Nickolas TL, Yoshita M, Paik MC, Kranwinkel G, et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke. 2007;38(12):3121-6.
39. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MMB. Kidney function is related to cerebral small vessel disease. Stroke. 2008;39(1):55-61.
40. Rost NS, Rahman R, Sonni S, Kanakis A, Butler C, Massasa E, et al. Determinants of white matter hyperintensity volume in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2010;19(3):230-5.
41. Jimenez-Conde J, Biffi A, Rahman R, Kanakis A, Butler C, Sonni S, et al. Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke. 2010; 41(3):437-42.
42. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke. 2005;36(1):50-5.
43. Rost NS, Rahman RM, Biffi A, Smith EE, Kanakis A, Fitzpatrick K, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75(19):1670-7.
44. Greenberg SM. Small vessels, big problems. N Engl J Med. 2006;354(14):1451-3.
45. Leys D, Englund E, Del Ser T, Inzitari D, Fazekas F, Bornstein N, et al. White matter changes in stroke patients. Relationship with stroke subtype and outcome. Eur Neurol. 1999;42(2):67-75.
46. Hijdra A, Verbeeten Jr B, Verhulst JA. Relation of leukoaraiosis to lesion type in stroke patients. Stroke. 1990;21(6):890-4.
47. Chen X, Wen W, Anstey KJ, Sachdev PS. Prevalence, incidence, and risk factors of lacunar infarcts in a community sample. Neurology. 2009;73(4):266-72.
48. Potter GM, Doubal FN, Jackson CA, Chappell FM, Sudlow CL, Dennis MS, et al. Counting cavitating lacunes underestimates the burden of lacunar infarction. Stroke. 2010;41(2):267-72.
49. O'Sullivan M. Leukoaraiosis. Pract Neurol. 2008;8(1):26-38.
50. Khan U, Porteous L, Hassan A, Markus HS. Risk factor pro file of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry. 2007;78(7):702-6.
51. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29(6):1177-81.
52. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, et al. Genetic variation in white matter hyperintensity volume in the Framingham study. Stroke. 2004;35(7): 1609-13.
53. Kochunov P, Glahn D, Winkler A, Duggirala R, Olvera RL, Cole S, et al. Analysis of genetic variability and whole genome linkage of whole-brain, subcortical, and ependymal hyperintense white matter volume. Stroke. 2009;40(12):3685-90.
54. Schmidt R, Schmidt H, Fazekas F, Kapeller P, Roob G, Lechner A, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol. 2000;20(7):1811-6.
55. Schmidt R, Schmidt H, Fazekas F, Launer LJ, Niederkorn K, Kapeller P, et al. Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension. 2001;38(1):110-5.
56. Hassan A, Lansbury A, Catto AJ, Guthrie A, Spencer J, Craven C, et al. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. J Neurol Neurosurg Psychiatry. 2002;72(3):343-6.
57. Sierra CCA, Gomez-Angelats E, Poch E, Sobrino J, de la Sierra A. Renin-angiotensin system genetic polymorphisms and cerebral white matter lesions in essential hypertension. Hypertension. 2002;39:343-7.
58. Hassan A, Gormley K, O'Sullivan M, Knight J, Sham P, Vallance P, et al. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke. 2004;35(3):654-9.
59. Henskens LHG, Kroon AA, van Boxtel MPJ, Hofman PAM, de Leeuw PW. Associations of the angiotensin ii type 1 receptor a1166c and the endothelial no synthase g894t gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke. 2005; 36:1869-73.
60. de Leeuw F-ERF, de Groot JC, van Duijn CM, Hofman A, van Gijn J, Breteler MMB. Interaction between hypertension, apoe, and cerebral white matter lesions. Stroke. 2004;35:1057-60.
61. DeStefano AL, Atwood LD, Massaro JM, Heard-Costa N, Beiser A, Au R, et al. Genome-wide scan for white matter hyperintensity: the Framingham Heart Study. Stroke. 2006;37(1): 77-81.
62. Turner ST, Fornage M, Jack Jr CR, Mosley TH, Kardia SLR, Boerwinkle E, et al. Genomic susceptibility loci for brain atrophy in hypertensive sibships from the GENOA Study. Hypertension. 2005;45(4):793-8.
63. Kochunov P, Glahn D, Lancaster J, Winkler A, Kent JW, Olvera RL, et al. Whole brain and regional hyperintense white matter volume and blood pressure. Stroke. 2010;41(10):2137-42.
64. Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996;272:676-80.
65. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795-803.
66. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516-7.
67. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma pro12ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
68. Assareh A, Mather KA, Schofield PR, Kwok JBJ, Sachdev PS. The genetics of white matter lesions. CNS Neurosci Ther. 2010;17(5):525-40.
69. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev Genet. 2005;6(2):95.
70. deBakker P, Rosand J. In search of genes for stroke. Lancet Neurol. 2007;6(5):383-4.
71. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 Mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a Mendelian condition causing stroke and vascular dementia. [Review] [10 refs]. Ann N Y Acad Sci. 1997;826(213):213-7.
72. Jung HH, Bassetti C, Tournier-Lasserve E, Vahedi K, Arnaboldi M, Arifi VB, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a clinicopathological and genetic study of a Swiss family. J Neurol Neurosurg Psychiatry. 1995;59(2): 138-43.
73. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia [see comments]. Nature. 1996;383(6602):707-10.
74. Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH, et al. Diagnostic strategies in CADASIL. Neurology. 2002;59(8):1134-8.
75. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 2007;6(2):149.
76. Oberstein SAJL, van den Boom R, Middelkoop HAM, Ferrari MD, Knaap YM, van Houwelingen HC, et al. Incipient CADASIL. Arch Neurol. 2003;60(5):707-12.
77. Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, et al. Heterogeneity in age-related white matter changes. Acta Neuropathol. 2011;122(2):171.
78. Schmidt H, Zeginigg M, Wiltgen M, Freudenberger P, Petrovic K, Cavalieri M, et al. Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain. 2011;134(11):3384-97.
79. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44(5):731-9.
80. Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127(11):2533-9.
81. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol. 1984;16(4):481-8.
82. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, KÃrppà M, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet. 1998;63(2):447.
83. Fujii T, Okuno T, Ito M, Motoh K, Hamazaki S, Okada S, Kusaka H, Mikawa H. CT, MRI, and autopsy findings in brain of a patient with MELAS. Pediatr Neurol. 1990;6(4):253-6.
84. Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2012;44(2):200.
85. Axelsson R, Röyttä M, Sourander P, Akesson HO, Andersen O. Hereditary diffuse leucoencephalopathy with spheroids. Acta Psychiatr Scand Suppl. 1984;314:1-65.
86. Wider C, Van Gerpen JA, DeArmond S, Shuster EA, Dickson DW, Wszolek ZK. Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD). Neurology. 2009;72(22): 1953-9.
87. Freeman SH, Hyman BT, Sims KB, Hedley-Whyte ET, Vossough A, Frosch MP, et al. Adult onset leukodystrophy with neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations. Brain Pathol. 2009;19(1):39.
88. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NIP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358(12): 1240-9.
89. Meschia JF. Stroke genome-wide association studies: the large numbers imperative. Stroke. 2010;41(4):579-80.
90. Lanktree MB, Dichgans M, Hegele RA. Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke. 2010;41(4):825-32.
91. Anderson C, Biffi A, Rahman R, Ross O, Jagiella J, Kissela B, Cole J, Cortellini L, Rost N, Cheng Y, Greenberg S, de Bakker P, Brown R, Brott T, Mitchell B, Broderick J, Worrall B, Furie K, Kittner S, Woo D, Slowik A, Meschia J, Saxena R, Rosand J, On behalf of the International Stroke Genetics Consortium. Common mitochondrial sequence variants in ischemic stroke. Ann Neurol. 2011;69(3):471-80. doi: 10.1002/ana.22108. Epub 2010 Sep 13.
92. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol. 2011;69(6):928-39.
93. Goldstein LB; A Primer on Stroke Prevention and Treatment: An overview based on AHA/ ASA Guidelines; 978-1-4051-8651-3; 2009; Wiley-Blackwell.